AI GxP validation for regulated life sciences
Industry

SI in Drug Discovery and Development: Where It Earns Its Place

Target identification, structure prediction, generative chemistry and property prediction are genuinely useful. What the evidence supports today, what remains unproven, and why the hard part was never the chemistry.

Cybroscape Technologies6 min read

Key takeaway

Target identification, structure prediction, generative chemistry and property prediction are genuinely useful. What the evidence supports today, what remains unproven, and why the hard part was never the chemistry.

Drug discovery is where this technology has the strongest claim in life sciences, and also where the claims run furthest ahead of the evidence. Both things are true at once, which makes it an awkward subject to write about honestly.

Here is a practitioner's view: what is genuinely working, what is promising but unproven, and why the bottleneck was never the part everyone is automating.

What is genuinely working

Protein structure prediction. The clearest success. Predicting three-dimensional structure from sequence went from a decades-long problem to a routine computational step, and it has changed how structural biology work is planned.

Virtual screening at scale. Computationally filtering very large compound libraries to a shortlist worth synthesising. Not new in principle, substantially better in practice.

Property and ADMET prediction. Estimating absorption, metabolism, toxicity and physicochemical properties early enough to kill a bad series before it consumes two years. Imperfect, and still useful — a prediction that is right most of the time is valuable when the alternative is synthesising everything.

Generative chemistry. Proposing novel structures against a target profile. Real, and the proposals still need a chemist to judge synthesisability and novelty.

Literature and data triage. Unglamorous and probably the highest return per pound spent — pulling signal out of internal data and published work that no team has time to read.

What is promising but not proven

Target identification. Proposing which biological target to pursue is the highest-value prediction in the industry and the hardest to validate, because the feedback loop is a decade long. Plenty of plausible candidates; little settled evidence about hit rates.

Clinical success prediction. Forecasting which molecules will survive trials. The industry would pay almost anything for this. Nobody has demonstrated it convincingly, and the base rates make it a genuinely hard statistical problem.

End-to-end discovery claims. Several companies have moved AI-originated molecules into clinical trials, which is a real milestone. What has not yet been established is whether such molecules succeed at a materially better rate than conventionally discovered ones — that evidence takes years to accumulate, and it is the only number that would settle the argument.

The honest position in late 2026 is that discovery timelines have genuinely compressed in the early stages, and the late stages — where most of the cost and nearly all of the attrition sits — look much as they did.

The bottleneck nobody is automating

Roughly nine in ten candidates that enter clinical development fail, most often on efficacy in humans or on safety that preclinical work did not predict. That failure is a biology problem, not a chemistry or computation problem.

Designing a molecule faster does not improve the odds that the target was the right one, or that the animal model predicted human response. Compressing a two-year discovery phase inside a twelve-year programme is real and worth having; it is not the order-of-magnitude change the headlines imply.

The place where better prediction would change the economics most is not generating candidates but killing bad ones earlier and more confidently — which is precisely the part that depends on evidence quality rather than model capability.

Where the regulated part begins

Most of discovery sits outside GxP, which is why teams move quickly there and are right to. The constraint arrives at the boundary: the moment a model's output supports a regulatory decision — a submission, a specification, a safety conclusion — it falls within scope and needs the evidence to match.

FDA's draft guidance on AI supporting regulatory decisions is built around exactly that distinction: the credibility you must demonstrate depends on the context of use and how much the model influences the decision. A tool that prioritises compounds for your chemists needs far less than one producing data in a filing.

Teams that get this wrong usually get it wrong late — a model used informally for two years turns out to underpin something in a submission. Deciding the boundary early is cheaper. See GxP AI validation and what regulated teams can deploy.

On the terminology: the US federal switch to "SI" changes nothing described above — see what the rename means for life sciences.

Where to go next

Explore Cybroscape GxP Copilot for AI-native validation, Cybroscape TraceDraft for source-traceable clinical documentation, or book a demo to see either on your own data.

US federal writingSuper Intelligence (SI)The term federal agencies now use
What does not change
  • Intended use defined and bounded
  • Validated before GxP use
  • Data integrity (ALCOA+)
  • A person decides what matters
  • Changes go through change control
EU GMP · Annex 22 · EU AI Act · MHRAArtificial intelligence (AI)The term in EU and UK rules
One quality systemTwo vocabularies, one set of controls
The US federal rename changes the word, not the obligations. EU GMP, the draft Annex 22, the EU AI Act and MHRA still say artificial intelligence, and the validation work is the same under either name.
See it on your own systemBring a URS or a system. We run GxP Copilot against it live on the call.
si drug discoveryai drug discovery 2026super intelligence drug developmentgenerative chemistry pharma
FAQ

Frequently Asked Questions

Prefer to talk first? Chat with us on WhatsApp or book a call with an expert.

Where is AI genuinely working in drug discovery?

Protein structure prediction is the clearest success. Virtual screening at scale, property and ADMET prediction, generative chemistry proposing novel structures, and literature and internal data triage are all delivering real value — the last being probably the highest return per pound spent.

Has AI been proven to improve clinical success rates?

Not yet. Several AI-originated molecules have entered clinical trials, which is a genuine milestone, but whether they succeed at a materially better rate than conventionally discovered molecules takes years of data to establish. That is the only number that would settle the argument, and it does not exist yet.

Why hasn't AI shortened drug development overall?

Because the bottleneck is biology, not chemistry. Roughly nine in ten candidates entering clinical development fail, mostly on efficacy in humans or unpredicted safety. Designing molecules faster does not improve the odds that the target was right or that preclinical models predicted human response.

Where would better prediction change the economics most?

Not in generating candidates but in killing bad ones earlier and more confidently. That depends on evidence quality rather than model capability, which is why data infrastructure usually matters more than the model.

When does discovery work fall under GxP?

Most discovery sits outside GxP. The constraint arrives when a model's output supports a regulatory decision — a submission, a specification, a safety conclusion. FDA's draft guidance scales the credibility you must show to the context of use and how much the model influences the decision, so decide that boundary early rather than discovering it late.

Keep reading

All articles
IndustryLife Sciences AI: What Regulated Teams Can Actually Deploy TodayThe deployment reality for AI in regulated life sciences: which use cases clear validation, which assurance evidence you need, how Annex 22 and Part 11 shape architecture, and a realistic path from pilot to production. · 11 min readIndustryWhat the Super Intelligence Rename Means for Life SciencesBeyond compliance: how the US switch from AI to SI lands across pharma and biotech (in R&D, clinical, manufacturing, commercial and the language of pitch decks) and which of it is substance rather than vocabulary. · 5 min readIndustryAI in Pharma 2026: Where It Is Actually WorkingA grounded look at where artificial intelligence is genuinely in production across pharmaceutical operations in 2026 (quality, validation, manufacturing, regulatory and clinical) and where the pilots are still stuck. · 11 min readIndustryCSV for Cell & Gene Therapy Manufacturers: Fast, Compliant, DefensibleThe validation model that fits the cadence of a CGT operation: CSA-first, modular by therapy program, inspection-ready by design. · 6 min readIndustrySI in Clinical Trials: What It Changes in Running a StudySite selection, recruitment, eligibility screening, risk-based monitoring and safety triage are where AI is already working in trials. What it does well, what must stay a clinician's judgement, and where GCP draws the line. · 6 min readIndustryValidation for Biotech Startups: From Seed to First Pharma-Partner AuditA staged validation programme that grows with a Seed/Series A/B biotech, without breaking budgets or missing the first partner audit. · 3 min readValidation PracticeValidation Debt: The Cost You Are Already CarryingValidation debt is the gap between what your documentation says a system is and what it actually is. Where it comes from, what it costs, and how to pay it down without a remediation project. · 6 min readThought LeadershipMost validation platform selections go wrong before the first demoValidation platform selections usually fail because the team never named its bottleneck: control, authoring or upstream process. Name it in one sentence, keep requirements short, make vendors work on your material and count the whole cost. · 3 min read

Bring a system. We'll show you the package.

Book a demo, or ask a validation lead a quick question on WhatsApp.

  • We reply within one business day
  • We run your URS live on the call
  • You get a clear plan for your system
Chat on WhatsApp

Book a demo

Four fields. The right specialist replies within one business day.

Your details stay private. We never share them.